Many prominent breakthroughs have been made in the field of cancer immunotherapy, especially the discovery of immune-checkpoint blockade (ICB) inhibitors targeting cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed cell death protein 1/programmed cell death protein ligand 1 (PD1/PDL1) [1]. This evidence concerns the gene PDCD1 and cancer.